We observed increased circulating levels of Th2 classical (IgE) and Th2 alternative (IgG4) antibody isotypes, consistent with well-described Th2-associated cytokine profiles and dysregulated immune responses in advanced disease and indicate that tumor progression and burden could contribute to altered phenotypes. The gene discussed is IGHE; the disease is neoplasm.